Owkin RlapsRisk™ BC is a cutting-edge AI diagnostic tool that enables pathologists and oncologists to accurately assess the risk of relapse in early breast cancer patients. By utilizing digital pathology slides (HES), RlapsRisk™ BC can effectively distinguish between low and high-risk breast cancer patients with ER+/HER2- cancer, helping clinicians to select the most appropriate treatment pathway for each individual patient.

One of the notable advantages of RlapsRisk™ BC is its high sensitivity, which is significantly greater than the sensitivity achieved by standard clinical scores. This means that the tool can accurately identify patients who are at risk of relapse and require more intensive treatment, as well as those who are at low risk and may be able to avoid unnecessary interventions.

RlapsRisk™ BC is designed specifically for adults with primary invasive breast cancer, making it a valuable tool for oncologists and pathologists who specialize in breast cancer treatment. Overall, the tool’s advanced AI capabilities and high sensitivity make it a promising new approach for improving breast cancer diagnosis and treatment.

Twitter Page of the Solution

linkedin Page of the Solution

Website of the Solution